To quantify this benefit , we conducted a surgical companion study to CALGB@ , a randomized phase II , @ factorial trial of neoadjuvant paclitaxel carboplatin bevacizumab ( B ) followed by doxorubicin plus cyclophosphamide B in stage II-III triple negative breast cancer .